229 related articles for article (PubMed ID: 26872380)
1. Inhibition of deubiquitinases primes glioblastoma cells to apoptosis in vitro and in vivo.
Karpel-Massler G; Banu MA; Shu C; Halatsch ME; Westhoff MA; Bruce JN; Canoll P; Siegelin MD
Oncotarget; 2016 Mar; 7(11):12791-805. PubMed ID: 26872380
[TBL] [Abstract][Full Text] [Related]
2. TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo.
Karpel-Massler G; Bâ M; Shu C; Halatsch ME; Westhoff MA; Bruce JN; Canoll P; Siegelin MD
Oncotarget; 2015 Nov; 6(34):36456-71. PubMed ID: 26474387
[TBL] [Abstract][Full Text] [Related]
3. Dual Inhibition of Bcl-2/Bcl-xL and XPO1 is synthetically lethal in glioblastoma model systems.
Shang E; Zhang Y; Shu C; Ishida CT; Bianchetti E; Westhoff MA; Karpel-Massler G; Siegelin MD
Sci Rep; 2018 Oct; 8(1):15383. PubMed ID: 30337641
[TBL] [Abstract][Full Text] [Related]
4. Metabolic reprogramming of glioblastoma cells by L-asparaginase sensitizes for apoptosis in vitro and in vivo.
Karpel-Massler G; Ramani D; Shu C; Halatsch ME; Westhoff MA; Bruce JN; Canoll P; Siegelin MD
Oncotarget; 2016 Jun; 7(23):33512-28. PubMed ID: 27172899
[TBL] [Abstract][Full Text] [Related]
5. WP1130 attenuates cisplatin resistance by decreasing P53 expression in non-small cell lung carcinomas.
Wang X; Bao Y; Dong Z; Chen Q; Guo H; Ziang C; Shao J
Oncotarget; 2017 Jul; 8(30):49033-49043. PubMed ID: 28446729
[TBL] [Abstract][Full Text] [Related]
6. Targeting deubiquitinase activity with a novel small-molecule inhibitor as therapy for B-cell malignancies.
Peterson LF; Sun H; Liu Y; Potu H; Kandarpa M; Ermann M; Courtney SM; Young M; Showalter HD; Sun D; Jakubowiak A; Malek SN; Talpaz M; Donato NJ
Blood; 2015 Jun; 125(23):3588-97. PubMed ID: 25814533
[TBL] [Abstract][Full Text] [Related]
7. Combined inhibition of RAC1 and Bcl-2/Bcl-xL synergistically induces glioblastoma cell death through down-regulation of the Usp9X/Mcl-1 axis.
Hlavac M; Dwucet A; Kast RE; Engelke J; Westhoff MA; Siegelin MD; Debatin KM; Wirtz CR; Halatsch ME; Karpel-Massler G
Cell Oncol (Dordr); 2019 Jun; 42(3):287-301. PubMed ID: 30859392
[TBL] [Abstract][Full Text] [Related]
8. Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis.
Kapuria V; Peterson LF; Fang D; Bornmann WG; Talpaz M; Donato NJ
Cancer Res; 2010 Nov; 70(22):9265-76. PubMed ID: 21045142
[TBL] [Abstract][Full Text] [Related]
9. WP1130 increases doxorubicin sensitivity in hepatocellular carcinoma cells through usp9x-dependent p53 degradation.
Liu H; Chen W; Liang C; Chen BW; Zhi X; Zhang S; Zheng X; Bai X; Liang T
Cancer Lett; 2015 Jun; 361(2):218-25. PubMed ID: 25749422
[TBL] [Abstract][Full Text] [Related]
10. USP9X inhibition improves gemcitabine sensitivity in pancreatic cancer by inhibiting autophagy.
Ma T; Chen W; Zhi X; Liu H; Zhou Y; Chen BW; Hu L; Shen J; Zheng X; Zhang S; Zhang B; Li H; Liang T
Cancer Lett; 2018 Nov; 436():129-138. PubMed ID: 30118840
[TBL] [Abstract][Full Text] [Related]
11. BH3-mimetics and BET-inhibitors elicit enhanced lethality in malignant glioma.
Ishida CT; Bianchetti E; Shu C; Halatsch ME; Westhoff MA; Karpel-Massler G; Siegelin MD
Oncotarget; 2017 May; 8(18):29558-29573. PubMed ID: 28418907
[TBL] [Abstract][Full Text] [Related]
12. PARP inhibition restores extrinsic apoptotic sensitivity in glioblastoma.
Karpel-Massler G; Pareja F; Aimé P; Shu C; Chau L; Westhoff MA; Halatsch ME; Crary JF; Canoll P; Siegelin MD
PLoS One; 2014; 9(12):e114583. PubMed ID: 25531448
[TBL] [Abstract][Full Text] [Related]
13. Antiviral activity of a small molecule deubiquitinase inhibitor occurs via induction of the unfolded protein response.
Perry JW; Ahmed M; Chang KO; Donato NJ; Showalter HD; Wobus CE
PLoS Pathog; 2012; 8(7):e1002783. PubMed ID: 22792064
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Mitochondrial Matrix Chaperones and Antiapoptotic Bcl-2 Family Proteins Empower Antitumor Therapeutic Responses.
Karpel-Massler G; Ishida CT; Bianchetti E; Shu C; Perez-Lorenzo R; Horst B; Banu M; Roth KA; Bruce JN; Canoll P; Altieri DC; Siegelin MD
Cancer Res; 2017 Jul; 77(13):3513-3526. PubMed ID: 28522750
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Bcl-2/Bcl-xL and c-MET causes synthetic lethality in model systems of glioblastoma.
Zhang Y; Ishida CT; Shu C; Kleiner G; Sanchez-Quintero MJ; Bianchetti E; Quinzii CM; Westhoff MA; Karpel-Massler G; Siegelin MD
Sci Rep; 2018 May; 8(1):7373. PubMed ID: 29743557
[TBL] [Abstract][Full Text] [Related]
16. Combined inhibition of Bcl-2/Bcl-xL and Usp9X/Bag3 overcomes apoptotic resistance in glioblastoma in vitro and in vivo.
Karpel-Massler G; Shu C; Chau L; Banu M; Halatsch ME; Westhoff MA; Ramirez Y; Ross AH; Bruce JN; Canoll P; Siegelin MD
Oncotarget; 2015 Jun; 6(16):14507-21. PubMed ID: 26008975
[TBL] [Abstract][Full Text] [Related]
17. A Synthetic Cell-Penetrating Dominant-Negative ATF5 Peptide Exerts Anticancer Activity against a Broad Spectrum of Treatment-Resistant Cancers.
Karpel-Massler G; Horst BA; Shu C; Chau L; Tsujiuchi T; Bruce JN; Canoll P; Greene LA; Angelastro JM; Siegelin MD
Clin Cancer Res; 2016 Sep; 22(18):4698-711. PubMed ID: 27126996
[TBL] [Abstract][Full Text] [Related]
18. 6-MOMIPP, a novel brain-penetrant anti-mitotic indolyl-chalcone, inhibits glioblastoma growth and viability.
Du S; Sarver JG; Trabbic CJ; Erhardt PW; Schroering A; Maltese WA
Cancer Chemother Pharmacol; 2019 Feb; 83(2):237-254. PubMed ID: 30426158
[TBL] [Abstract][Full Text] [Related]
19. Context-dependent function of the deubiquitinating enzyme USP9X in pancreatic ductal adenocarcinoma.
Cox JL; Wilder PJ; Wuebben EL; Ouellette MM; Hollingsworth MA; Rizzino A
Cancer Biol Ther; 2014 Aug; 15(8):1042-52. PubMed ID: 24841553
[TBL] [Abstract][Full Text] [Related]
20. USP9X stabilizes BRCA1 and confers resistance to DNA-damaging agents in human cancer cells.
Lu Q; Zhang FL; Lu DY; Shao ZM; Li DQ
Cancer Med; 2019 Nov; 8(15):6730-6740. PubMed ID: 31512408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
